Therapeutic Equivalency Clinical Trial
Official title:
Bioavailability of a Formulation of Levonorgestrel and Ethinyl Estradiol 15.0 mg/0.03 mg Coated Tablets With Regards to the Marketed Reference Product
This study will investigate the bioavailability in women of 2 tablet formulations containing Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg. The study will be performed at a single site with 36 subjects. Participants will take 2 tablets of the test product and reference product in 2 periods and 2 sequences (either test after reference or reference after test). There will be a washout of at least 14 days between each study period.
The primary objective of the study is to investigate the relative bioavailability of Levonorgestrel and Ethinyl estradiol of 2 tablet formulations with Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg and to demonstrate bioequivalence of both formulations in terms of rate and extent of absorption: - Test Product: Product manufactured by Laboratorios Andrómaco S.A. - Reference Product: Microgynon [Trademark], product of Bayer AG, Brasil. The 90% confidence intervals for the intra-subject coefficient of variation (Test versus Reference Product) for the main pharmacokinetic parameters área under the plasma concentration-time curve from time zero to time t (AUC0-t) and from time zero to infinite (AUC0-∞), and maximum plasma concentration (Cmax) for total Levonorgestrel and Ethinyl estradiol will be determined. Participants will be confined in the study site for approximately 34 hours during each study period (for 10 hours pre-dosing and for 24 hours post dosing) during which pharmacokinetic (PK) blood samples will be obtained. 21 blood samples will be taken up to 24 hours after the administration in each period. Participants will return to the site to provide additional blood samples at 48 h, and 72 h postdose. The washout period between the two study periods will be at least 14 days. A validated LC-MS/MS bio-analytical method will be used for estimation of plasma levels of Ethinyl-estradiol and Levonorgestrel. The safety objective is to evaluate the tolerability of both formulations in women by collecting adverse events. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04467346 -
Bioequivalence Study Between Temozolomide Oral Suspension (Ped-TMZ) and Temodal® Capsules
|
Phase 1 | |
| Completed |
NCT00807118 -
Phase 1, Single Dose, Crossover Study to Determine Bioequivalence and to Investigate Food Effect
|
Phase 1 | |
| Withdrawn |
NCT01405170 -
A Bioequivalence Study Comparing Methylprednisolone Suspension to Methylprednisolone Tablets Under Fed Conditions
|
Phase 1 | |
| Completed |
NCT04885660 -
Bioequivalence Evaluation of Two Fixed-dose Combination of Lisinopril 10mg/Levamlodipine Besylate 5mg in Healthy Chinese Subjects
|
Phase 1 | |
| Completed |
NCT05786339 -
Bioequivalence Study of Two Irbesartan in Healthy Chinese Subjects
|
Phase 1 | |
| Completed |
NCT00709189 -
Bioequivalence Study of the Oral Contraceptive Tablet Containing Norgestimate (NGM)/Ethinyl Estradiol (EE) With or Without Folic Acid in Healthy Women.
|
Phase 1 | |
| Completed |
NCT00658541 -
Fed Bioequivalence Study of Zolpidem Tartrate Tablets and Ambien® Tablets
|
Phase 1 | |
| Completed |
NCT00685165 -
Fasted Bioequivalence Study of Primidone Tablets and Mysoline Tablets
|
Phase 1 | |
| Completed |
NCT00997789 -
Bioequivalence of Rebamipide in Korean
|
N/A | |
| Completed |
NCT00684762 -
Fasted Bioavailability Study of Cilostazol Tablets, 100 mg
|
Phase 1 | |
| Recruiting |
NCT04814589 -
Bioequivalence of Ezetimibe Tablets in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT03631316 -
Pharmacokinetic Parameters of Innovative Valganciclovir Versus Generic Valganciclovir
|
N/A | |
| Recruiting |
NCT04438720 -
Bioequivalence of Extended Release Nifedipine Tablets in Healthy Chinese Subjects
|
Phase 1 | |
| Completed |
NCT01359163 -
A Study To Determine Bioequivalence Between The Commercial Femulen Tablets And A Reformulation Of Femulen Tablets In Healthy Female Subjects
|
Phase 1 | |
| Completed |
NCT00650221 -
Fasting Bioequivalence Study of Pravastatin Sodium 80 mg Tablets Versus Pravachol® 80 mg Tablets In Normal Healthy Subjects
|
Phase 1 | |
| Completed |
NCT00648544 -
Fed, Bioequivalence Study of Pravastatin Sodium 80 mg Tablets Versus Pravachol® 80 mg Tablets In Subjects
|
Phase 1 | |
| Completed |
NCT05225974 -
A Randomized Phase 1 Study of Liralutide Injection in Healthy Chinese Subjects
|
Phase 1 | |
| Withdrawn |
NCT01405157 -
A Bioequivalence Study Comparing Methylprednisolone Suspension To Methylprednisolone Tablets Under Fasting Conditions
|
Phase 1 | |
| Withdrawn |
NCT01405131 -
A Bioequivalence Study Comparing Methylprednisolone Suspension To Methylprednisolone Tablets
|
Phase 1 | |
| Completed |
NCT06050343 -
Comparative Study of Rinsulin R (GEROPHARM) and Humulin Regular (Eli Lilly) Euglycemic Hyperinsulinemic Clamp Method
|
N/A |